Hungary Pharmaceuticals & Healthcare Q4 2019
Hungary's pharmaceutical market is set to continue its sluggish growth outlook, as deficiencies within public healthcarefunding continues to drag on medicine sales. The government's repressive reimbursement criteria has led to increasingcontributions from industry stakeholders, while public drug funding has stagnated. Patients will bear a rising burden of drug costs,reducing affordability and access to treatments. Nonetheless, improving public procurement practices would place downwardpressure on drug prices, thus increasing long term market sustainability as the population ages.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook